SRPK1 Inhibition, As A Way Of Targeting Pro-Angiogenic VEGF-A Production In Ocular Tumours

被引：0
|
作者：
Gammons, Melissa [1 ]
Coupland, Sarah [2 ]
Dick, Andrew [3 ,4 ]
Bates, David [1 ]
机构：
[1] Univ Bristol, Dept Physiol & Pharmacol, Bristol, Avon, England
[2] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England
[3] Univ Bristol, Sch Clin Sci, Bristol, Avon, England
[4] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2013年 / 54卷 / 15期
关键词：
589; melanoma; 744; tumors; 748 vascular endothelial growth factor;
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4526
引用
收藏
页数：2
相关论文
共 45 条
  • [1] SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform
    Hatcher, John M.
    Wu, Guowei
    Zeng, Chuyue
    Zhu, Jie
    Meng, Fan
    Patel, Sherrina
    Wang, Wenqiu
    Ficarro, Scott B.
    Leggett, Alan L.
    Powell, Chelsea E.
    Marto, Jarrod A.
    Zhang, Kang
    Ngo, Jacky Chi Ki
    Fu, Xiang-Dong
    Zhang, Tinghu
    Gray, Nathanael S.
    CELL CHEMICAL BIOLOGY, 2018, 25 (04): : 460 - +
  • [2] Systems biology of pro-angiogenic therapies targeting the VEGF system
    Mac Gabhann, Feilim
    Qutub, Amina A.
    Annex, Brian H.
    Popel, Aleksander S.
    WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE, 2010, 2 (06) : 694 - 707
  • [3] Pro-angiogenic and anti-angiogenic therapies targeting the VEGF-VEGFR system
    Mac Gabhann, Feilim
    Popel, Aleksander S.
    FASEB JOURNAL, 2009, 23
  • [4] SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
    Mavrou, Athina
    Oltean, Sebastian
    PHARMACOLOGICAL RESEARCH, 2016, 107 : 276 - 281
  • [5] The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A
    S Dedieu
    X Canron
    HR Rezvani
    M Bouchecareilh
    F Mazurier
    R Sinisi
    M Zanda
    M Moenner
    A Bikfalvi
    S North
    BMC Medicine, 8
  • [6] The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A
    Dedieu, S.
    Canron, X.
    Rezvani, H. R.
    Bouchecareilh, M.
    Mazurier, F.
    Sinisi, R.
    Zanda, M.
    Moenner, M.
    Bikfalvi, A.
    North, S.
    BMC MEDICINE, 2010, 8
  • [7] Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
    Gammons, M. V.
    Lucas, R.
    Dean, R.
    Coupland, S. E.
    Oltean, S.
    Bates, D. O.
    BRITISH JOURNAL OF CANCER, 2014, 111 (03) : 477 - 485
  • [8] Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
    M V Gammons
    R Lucas
    R Dean
    S E Coupland
    S Oltean
    D O Bates
    British Journal of Cancer, 2014, 111 : 477 - 485
  • [9] Targeting SRPK1 with novel potent and selective small molecule inhibitors inhibits choroidal neovascularisation through modulating VEGF-A alternative splicing
    Bates, David O.
    Toop, Hamish
    Daubney, James
    Stewart, Elizabeth
    Morris, Jonathan
    Batson, Jennifer
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [10] SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases
    Oltean, Sebastian
    Gammons, Melissa
    Hulse, Richard
    Hamdollah-Zadeh, Maryam
    Mavrou, Athina
    Donaldson, Lucy
    Salmon, Andrew H.
    Harper, Steve J.
    Ladomery, Michael R.
    Bates, David O.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 831 - 835
12345